- Home
- EBMT vs AGEN Comparison
EBMT vs AGEN Comparison
Compare EBMT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- AGEN
- Stock Information
- Founded
- EBMT 1922
- AGEN 1994
- Country
- EBMT United States
- AGEN United States
- Employees
- EBMT N/A
- AGEN N/A
- Industry
- EBMT Major Banks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBMT Finance
- AGEN Health Care
- Exchange
- EBMT Nasdaq
- AGEN Nasdaq
- Market Cap
- EBMT 134.3M
- AGEN 123.6M
- IPO Year
- EBMT N/A
- AGEN 2000
- Fundamental
- Price
- EBMT $16.57
- AGEN $3.69
- Analyst Decision
- EBMT
- AGEN Buy
- Analyst Count
- EBMT 0
- AGEN 2
- Target Price
- EBMT N/A
- AGEN $14.50
- AVG Volume (30 Days)
- EBMT 20.4K
- AGEN 453.8K
- Earning Date
- EBMT 10-28-2025
- AGEN 11-11-2025
- Dividend Yield
- EBMT 3.53%
- AGEN N/A
- EPS Growth
- EBMT 58.15
- AGEN N/A
- EPS
- EBMT 1.72
- AGEN N/A
- Revenue
- EBMT $87,531,000.00
- AGEN $101,706,000.00
- Revenue This Year
- EBMT N/A
- AGEN $60.49
- Revenue Next Year
- EBMT $5.45
- AGEN N/A
- P/E Ratio
- EBMT $9.64
- AGEN N/A
- Revenue Growth
- EBMT 9.36
- AGEN N/A
- 52 Week Low
- EBMT $14.35
- AGEN $1.38
- 52 Week High
- EBMT $18.49
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- EBMT 46.74
- AGEN 38.01
- Support Level
- EBMT $16.12
- AGEN $3.77
- Resistance Level
- EBMT $16.60
- AGEN $4.11
- Average True Range (ATR)
- EBMT 0.30
- AGEN 0.24
- MACD
- EBMT -0.02
- AGEN -0.02
- Stochastic Oscillator
- EBMT 55.56
- AGEN 6.19
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).